HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Competing interest statement Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vesga, L Articles by Mahadevan, U Search for Related Content PubMed PubMed Citation Articles by Vesga, L Articles by Mahadevan, U

Adalimumab use in pregnancy

Division of Gastroenterology, University of California, San Francisco, USA

Correspondence to:
Correspondence to:
Dr U Mahadevan MD
Division of Gastroenterology, University of California, 2330 Post Street, #610, San Francisco, CA 94115, USA; umamah@itsa.ucsf.edu

Keywords: adalimumab; pregnancy; Crohn’s disease

The first 150 words of the full text of this article appear below.

Infliximab, a chimeric antibody to tumour necrosis factor alpha (TNF-), has demonstrated efficacy for the induction and maintenance of remission in patients with Crohn’s disease.^1,2 Antibodies to the chimeric component of infliximab can lead to infusion reactions and possible loss of response.³ A human recombinant monoclonal antibody to TNF-, adalimumab, has recently demonstrated safety and efficacy for induction of remission in Crohn’s disease.⁴ It has also been effective in patients who have lost response to infliximab.⁵ Currently, this drug is FDA approved for the treatment of rheumatoid arthritis but it is being administered off label to patients with Crohn’s disease who are intolerant of infliximab. The safety profile during pregnancy is not well known for either drug. We report a patient who has had two successful pregnancies, one while on infliximab and the other while on adalimumab.

A 34 year old woman with longstanding ileocolonic and perianal Crohn’s . . . [Full text of this article]

This article has been cited by other articles:

				D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, J Sieper, P Emery, E C Keystone, M H Schiff, P Mease, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 Ann Rheum Dis, November 1, 2007; 66(suppl_3): iii2 - iii22. [Full Text] [PDF]

				D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, P Emery, E C Keystone, M H Schiff, P L C M van Riel, M E Weinblatt, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006 Ann Rheum Dis, November 1, 2006; 65(suppl_3): iii2 - iii15. [Full Text] [PDF]

				F. Pucino Jr., P. T. Harbus, and R. Goldbach-Mansky Use of biologics in rheumatoid arthritis: Where are we going? Am. J. Health Syst. Pharm., September 15, 2006; 63(18 Suppl 4): S19 - S41. [Abstract] [Full Text] [PDF]

				U Mahadevan Fertility and pregnancy in the patient with inflammatory bowel disease. Gut, August 1, 2006; 55(8): 1198 - 1206. [Full Text] [PDF]